Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BMS-303141 is a potent ATP-citrate lyase (ACL) inhibitor (IC50: 0.13 uM, human recombinant ACL).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 39.00 | |
5 mg | In stock | $ 61.00 | |
10 mg | In stock | $ 79.00 | |
25 mg | In stock | $ 143.00 | |
50 mg | In stock | $ 282.00 | |
100 mg | In stock | $ 443.00 | |
500 mg | In stock | $ 992.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 63.00 |
Description | BMS-303141 is a potent ATP-citrate lyase (ACL) inhibitor (IC50: 0.13 uM, human recombinant ACL). |
Targets&IC50 | ACL:0.13 μM |
In vitro | BMS-303141 shows inhibition of total lipid syntheses with an IC50 of 8 μM in HepG2 cells. BMS-303141 shows no cytotoxicity up to 50 lM under a cell-based Alamar Blue cytotoxicity assay, indicating the observed inhibition of lipid synthesis is not a result of compound-induced cytotoxicity[1]. |
In vivo | Chronic oral administration of BMS-303141 to mice on a high-fat diet reduces plasma cholesterol and triglycerides by approximately 20-30% and fasting plasma glucose by 30-50%. Continued treatment with BMS-303141 gradually inhibits weight gain and decreases adiposity without affecting food consumption. BMS-303141 displays an oral bioavailability of 55% and a relatively brief half-life of 2.1 hours[1]. |
Synonyms | BMS 303141 |
Molecular Weight | 424.3 |
Formula | C19H15Cl2NO4S |
CAS No. | 943962-47-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (129.63 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BMS-303141 943962-47-8 Metabolism ATP Citrate Lyase inhibit BMS303141 BMS 303141 Inhibitor ACLY inhibitor